Second CAR t infusion: a new hope for lymphoma patients who relapse?
NCT ID NCT05794958
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a second infusion of the CAR T-cell therapy Axi-Cel (called Axi-Cel-2) is safe for people with high-risk large B-cell lymphoma whose cancer came back after standard CAR T treatment. About 20 adults will receive the second infusion and be monitored closely for side effects. The goal is to see if this approach can be a safe option for controlling the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axicabtagene ciloleucel (Axi-Cel-2), a CAR T-cell therapy
What this could lead to
If successful, this could offer a second chance at controlling lymphoma for patients who relapse after their first CAR T treatment.
What could go wrong
This is a very early (phase 1) and small (20 people) safety study. The second infusion may cause severe side effects like cytokine release syndrome or neurotoxicity, and it may not effectively control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94305, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact